oxis turbohaler 4.5 µg/dosis inhalatiepdr. multidos. cont.
astrazeneca sa-nv - formoterolfumaraatdihydraat 10 mg/g - inhalatiepoeder - 4,5 µg/dose - formoterolfumaraatdihydraat 4.5 µg/dosis - formoterol
plendil 10 mg retard tabl. verl. afgifte
astrazeneca sa-nv - felodipine 10 mg - tablet met verlengde afgifte - felodipine 10 mg - felodipine
plendil 5 mg retard tabl. verl. afgifte
astrazeneca sa-nv - felodipine 5 mg - tablet met verlengde afgifte - felodipine 5 mg - felodipine
rhinocort turbohaler 100 100 µg/dose snuifpoeder inhalator
astrazeneca sa-nv - budesonide 100 µg/dosis - snuifpoeder - 100 µg - budesonide 100 µg/dosis - budesonide
tenif 50 mg - 20 mg harde caps.
astrazeneca sa-nv - nifedipine 20 mg; atenolol 50 mg - capsule, hard - 50 mg - 20 mg - nifedipine 20 mg; atenolol 50 mg - atenolol and other antihypertensives
trixeo aerosphere
astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - longaandoening, chronisch obstructief - geneesmiddelen voor obstructieve aandoeningen van de luchtwegen, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.
calquence
astrazeneca ab - acalabrutinib - leukemie, lymfocytisch, chronisch, b-cel - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.
lumoxiti
astrazeneca ab - moxetumomab pasudotox - leukemie, harige cel - antineoplastische middelen - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).
evusheld
astrazeneca ab - tixagevimab, cilgavimab - covid-19 virus infection - prevention of covid-19.
saphnelo
astrazeneca ab - anifrolumab - lupus erythematosus, systemisch - immunosuppressiva - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.